论文部分内容阅读
背景:目前国内外尚没有治疗儿童孤独症的金标准,康复治疗效果不佳。目的:评价脐血单个核细胞和脐带间充质干细胞治疗儿童孤独症的临床安全性和有效性。方法:37例儿童孤独症患者非随机分为脐血组、混合组和对照组。脐血组应用脐血单个核细胞加康复训练治疗;混合组联合应用脐血单个核细胞和脐带间充质干细胞加康复训练治疗;对照组单纯行康复训练治疗。脐血组和混合组患者在干细胞治疗前和首次治疗后1,2,6个月分别行相关指标实验室检查,并观察有无不良反应发生。3组患者在治疗前和首次治疗后1,2,6个月分别行儿童孤独症评定量表(CARS)和异常行为量表(ABC)评估。结果与结论:脐血组和混合组患者在干细胞治疗前和首次治疗后1,2,6个月相关指标实验室检查未发现有意义异常变化,干细胞治疗后无严重不良反应发生;根据CARS和ABC评分,3组治疗均有效,其疗效比较:混合组优于脐血组,脐血组优于对照组。
Background: At present, there is no gold standard for the treatment of autism in children at home and abroad, and the effect of rehabilitation treatment is poor. Objective: To evaluate the clinical safety and efficacy of umbilical cord blood mononuclear cells and umbilical cord mesenchymal stem cells in children with autism. Methods: 37 children with autism were randomly divided into umbilical cord blood group, mixed group and control group. Umbilical cord blood mononuclear cells plus rehabilitation training; mixed group of umbilical cord blood mononuclear cells and umbilical cord blood cells plus mesenchymal stem cells plus rehabilitation training; control group simply rehabilitation training. Umbilical cord blood group and mixed group patients before treatment of stem cells and 1, 2, 6 months after the first treatment were related indicators of laboratory tests and to observe the occurrence of adverse reactions. Three groups of children were evaluated by CARS and ABC before treatment and one, two and six months after the first treatment respectively. RESULTS AND CONCLUSION: No significant abnormal changes were found in the cord blood group and mixed group before and after 1, 2 and 6 months after the first treatment. No serious adverse reactions occurred after stem cell treatment. According to CARS and ABC score, three groups of treatment are effective, the efficacy comparison: mixed group is better than cord blood group, cord blood group is better than control group.